The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer

Endocrinology

Volumn 149, Issue 8, 2008, Pages 4035-4042

  Foster, Paul A ^a   Woo, L W Lawrence ^b   Potter, Barry V L ^b   Reed, Michael J ^a   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; STERYL SULFATASE; STX 140; STX 213; STX 64;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROL GROUP; DRUG EFFICACY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; HORMONE DEPENDENCE; LINEAR REGRESSION ANALYSIS; LIVER FUNCTION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; CARCINOMA; CELL PROLIFERATION; COUMARINS; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTRENES; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; OVARIECTOMY; STERYL-SULFATASE; SULFONAMIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 47949106800     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0223     Document Type: Article

References (52)

1. Sherman ME, Sturgeon S, Brinton L, Kurman RJ 1995 Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem Suppl 23:160-164
2. Sherman ME 2000 Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295-308
3. Thoma DB 1984 Do hormones cause cancer? Cancer 53:595-604
4. Kelsey JL 1982 A case control study of cancer of the endometrium. Am J Epidemiol 116:333-342
5. Ryan KJ 1975 Cancer risk and estrogen use in the menopause. N Engl J Med 293:1199-1200
6. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26:171-202
7. Reed MJ, Purohit A, Woo LWL, Potter BVL 1996 The development of steroid sulphatase inhibitors. Endocr Relat Cancer 3:9-23
8. Dickson RB, Thompson EW, Lippman ME 1990 Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol 37:305-316
9. Reed MJ, Beranek PA, Ghilchik MW, James VH 1986 Estrogen production and metabolism in normal postmenopausal women and postmenopausal women with breast or endometrial cancer. Eur J Cancer Clin Oncol 22:1395-1400
10. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:2900-2906
11. Pasqualini JR, Chetrite GS 1999 Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 69:287-292
12. Falany JL, Falany CN 1996 Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56:1551-1555
13. Falany JL, Macrina N, Falany CN 2002 Regulation of MCF-7 breast cancer cell growth by β-estradiol sulfonation. Breast Cancer Res Treat 74:167-176
14. Bonney RC, Scanlon MJ, Jones DL, Reed MJ, Anderson MC, James VH 1986 The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer. Eur J Cancer Clin Oncol 22:953-961
15. Vermeulen-Meiners C, Poortman J, Haspels AA, Thijssen JH 1986 The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J Steroid Biochem 24:1073-1078
16. Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA, Thijssen JH 2003 Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 129:245-249
17. Ito K, Utsunomiya H, Yaegashi N, Sasano H 2007 Biological roles of estrogen and progesterone in human endometrial carcinoma: new developments in potential endocrine therapy for endometrial cancer. Endocr J 54:667-679
18. Krasner C 2007 Aromatase inhibitors in gynecologic cancers J Steroid Biochem Mol Biol 106:76-80
19. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A 2004 The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14:650-658
20. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB 2000 A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:212-216
21. Krasner C, Debernardo R, Findley M, Penson R, Matulonis U, Atkinson T, Roche M, Seiden MV 2005 Phase II trial of anastrozole in combination with gefitinib in women with asymptomatic mullerian cancer: ASCO Annual Meeting Proceedings. J Clin Oncol 23:5063
22. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J-I, Okamura K, Yaegashi N, Sasano H 2006 17β-Hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 248:136-140
23. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BVL, Reed MJ, Purohit A 2008 17β-Hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 122:1931-1940
24. Yamamoto T, Kitawaki J, Urabe M, Honjo H, Tamura T, Noguchi T, Okada H, Sasaki H, Tada A, Terashima Y 1993 Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 44:463-468
25. Utsunomiya H, Ito K, Suzuki T, Kitamura T, Kaneko C, Nakata T, Niikura H, Okamura K, Yaegashi N, Sasano H 2004 Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 10:5850-5856
26. Purohit A, Woo LWL, Potter BVL, Reed MJ 2000 In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 60:3394-3396
27. Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LWL, Potter BVL, Reed MJ, Purohit A 2006 In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 12:5543-5549
28. Foster PA, Chander SK, Parsons MF, Newman SP, Woo LWL, Potter BVL, Reed MJ, Purohit A 4 October 2007 Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat [Epub ahead of print]
29. Howarth NM, Purohit A, Reed MJ, Potter BVL 1994 Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 37:219-221
30. Woo LWL, Purohit A, Malini B, Reed MJ, Potter BVL 2000 Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 7:773-791
31. Malini B, Purohit A, Ganeshapillai D, Woo LWL, Potter BVL, Reed MJ 2000 Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J Steroid Biochem Mol Biol 75:253-258
32. Stanway SJ, Purohit A, Woo LWL, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BVL, Reed MJ, Coombes RC 2006 Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 12:1585-1592
33. Stanway SJ, Delavault P, Purohit A, Woo LWL, Thurieau C, Potter BVL, Reed MJ 2007 Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 12:370-374
34. Fischer DS, Chander SK, Woo LWL, Fenton JC, Purohit A, Reed MJ, Potter BVL 2003 Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 84:343-349
35. Fischer DS, Woo LWL, Mahon MF, Purohit A, Reed MJ, Potter BVL 2003 D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg Med Chem 11:1685-1700
36. Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL 2006 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 49:7683-7696
37. Raobaikady B, Purohit A, Chander SK, Woo LW, Leese MP, Potter BVL, Reed MJ 2003 Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 84:351-358
38. Raobaikady B, Reed MJ, Leese MP, Potter BVL, Purohit A 2005 Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer 117:150-159
39. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BVL, Reed MJ 2004 Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109:533-540
40. Chander SK, Foster PA, Leese MP, Newman SP, Potter BVL, Purohit A, Reed MJ 2007 In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96:1368-1376
41. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BVL, Reed MJ 2004 Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90:932-937
42. Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BVL, Reed MJ, Purohit A 24 October 2007 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat [Epub ahead of print]
43. Seibert K, Shafie SM, Triche TJ, Whang-Peng JJ, O'Brien SJ, Toney JH, Huff KK, Lippman ME 1983 Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 43:2223-2239
44. Brunner N, Spang-Thomsen M, Vindelov L, Wolff J, Engelholm SA 1985 Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 21:1349-1354
45. Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS 2005 Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005 97:632-642
46. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ 1995 In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 63:106-111
47. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W, Gynecologic Oncology Group study 2004 Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:10-14
48. Decruze SB, Green JA 2007 Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17:964-978
49. Gadducci A, Cosio S, Genazzani AR 2006 Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58:242-256
50. Dai A, Holmes AM, Nguyen T, Davies S, Theele DP, Verschraegen C, Leslie KK 2005 A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res 65:9517-9524
51. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T 2006 Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101:158-167
52. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT 1999 Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744